1. Home
  2. |Professionals
  3. |Neil Campbell

Neil Campbell

Senior Counsel
Senior Counsel
bmNhbXBiZWxsQGNyb3dlbGwuY29t
VCardLinkedIn
VCardLinkedIn

Areas of Focus

Overview

Neil Campbell is an experienced transactional attorney who counsels clients on an array of transactions relating to drug and medical device research, development, and manufacturing.

Neil structures, drafts, and negotiates licensing and collaboration agreements, academic agreements, technology evaluation agreements, and manufacturing and other service agreements. He also regularly assists clients in navigating complex multinational supply chain and clinical trial arrangements for small molecule and biologic products, including cell and gene therapies.

Prior to his legal career, Neil spent a decade as a biomedical researcher. In that role, he gained a deep scientific and industry context that enables him to appreciate clients’ scientific development strategies and provide them with thoughtful and pragmatic counsel.

Career & Education

    • Life Sciences Transactions Associate, AmLaw 50 firm
      • Representation of public and private pharmaceutical and biotechnology companies, ranging from startups to multinational corporations in the US, Europe, and Japan, in a broad range of life sciences transactional matters.
    • Preclinical Imaging Shared Resource Manager, Rutgers Cancer Institute of New Jersey
    • Life Sciences Transactions Associate, AmLaw 50 firm
      • Representation of public and private pharmaceutical and biotechnology companies, ranging from startups to multinational corporations in the US, Europe, and Japan, in a broad range of life sciences transactional matters.
    • Preclinical Imaging Shared Resource Manager, Rutgers Cancer Institute of New Jersey

    • University of Plymouth, B.S.
    • University of Plymouth, MRes
    • Rutgers Law School, J.D., cum laude
    • University of Plymouth, B.S.
    • University of Plymouth, MRes
    • Rutgers Law School, J.D., cum laude

    • New York
    • New York

    • Member, Alumni Steering Committee for the Rutgers Center for Corporate Law and Governance
    • Member, Alumni Steering Committee for the Rutgers Center for Corporate Law and Governance

Representative Matters

Manufacturing and R&D Agreements

  • Drafted and negotiated multiple complex development and manufacturing agreements for CAR-T product supply chain of a clinical-development stage company client.
  • Represented early-stage drug development accelerator company in development and supply agreements for its gene therapy treatment for a rare genetic disorder.
  • Drafted and negotiated sponsored research and other agreements with academic institutions in the U.S., EU, and UK.
  • Provided strategic legal counseling to multiple drug development companies in connection with large, multicenter, global Phase 2 and 3 clinical studies for small molecule and biologic products.

Licensing and Collaboration Transactions

  • Represented multiple early-stage, venture-backed drug development companies in research collaborations to discover and/or generate multi-specific or conjugated antibodies directed against designated drug targets.
  • Represented pioneering biotechnology company in a collaboration and option-to-license agreement with global biopharmaceutical company to develop multi-specific biologics for multiple targets in oncology leveraging the biotechnology company’s platform, with an upfront payment of $65 million, up to $1.4 billion in option fees and milestones, as well as tiered royalty payments on net sales.
  • Represented Japanese biotechnology company in a strategic collaboration agreement with global biotechnology company, subsequent to the assignment of TMS-007 global rights from Biogen to JIXING.
  • Represented a biotechnology company developing next-generation cell therapies in a license and collaboration with a clinical-stage genome editing company to advance allogeneic CRISPR-Edited NK cell therapies, with milestones up to $920 million plus royalties.
  • Represented a commercial-stage biotechnology company in a research and development collaboration to develop TCR-based immunotherapies for solid tumors, with an option to exclusively license candidates resulting from the collaboration.
  • Represented a leading biotechnology company in a license agreement with Agios for novel siRNA for potential.